Axinix 5

Axinix 5 mg has shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.

Dose increase or reduction recommended base on individual safety and tolerability. Over the course of treatment, patients who tolerate Axitinib for at least two consecutive weeks with no adverse reactions > Grade 2 (according to the Common Toxicity Criteria for Adverse Events), are normotensive, and are not receiving anti-hypertension medication, may their dose increase.

When a dose increase from 5 mg twice daily recommended. The Axitinib dose may be increased to 7 mg twice daily, and further to 10 mg twice daily using the same criteria. Over the course of treatment, management of some adverse drug reactions may require temporary interruption or permanent discontinuation and/or dose reduction of Axitinib therapy. If dose reduction from 5 mg twice daily require, the recommend dose is 3 mg twice daily. If additional dose reduction require, the recommend dose is 2 mg twice daily.

Selected adverse reactions (all grades) that report in < 10% of patients treated with Axinix included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), glossodynia (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-vein occlusion/thrombosis (1%), polycythemia (1%), and transient ischemic attack (1%).

Pregnancy Category D. Axinix can cause fetal harm when administered to a pregnant woman base on its mechanism of action. There are no adequate and well-controlled studies in pregnant women using Axitinib. In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.

 

Women of childbearing potential should advised to avoid becoming pregnant while receiving Axinix . If this drug use during pregnancy, or if a patient becomes pregnant while receiving this drug, the patient apprise of the potential hazard to the fetus.

 

Nursing Mothers: It is not known whether Axinix excrete in human milk. Many drugs are excreted in human milk, and Axitinib could potentially cause serious adverse reactions in nursing infants. Therefore, you should decide whether to discontinue nursing or to stop using the drug. Consider the importance of Axitinib to the mother when making this decision.

 

Patient with HTN, cardiac disease, history of or risk for thrombosis. Patients taking strong CYP3A4 inhibitors. Withhold treatment at least 24 hr prior to scheduled surgery. Moderate hepatic impairment (Child-Pugh Class B). Pregnancy.